MS & Immune Disorders

Filter Your Results




Early Treatment of Clinically Isolated Syndrome With Interferon ß-1b Shows Benefit Over a 15-Year Period

Saturday, March 02, 2019—Patients with clinically isolated syndrome (CIS) who were treated with interferon ß-1b (IFN) show long term benefits of early treatment (initiation within 2 years of dia…

Partnership Between Community and Academic Healthcare Can Improve Standardization of Imaging Protocols for Multiple Sclerosis

Saturday, March 02, 2019—Guidelines exist for standardized MRI for monitoring disease activity in patients with multiple sclerosis (MS) and enhance quality of care for patients as well as creating the…

Rates of Initiating Disease-Modifying Treatment for Multiple Sclerosis Remain Low

Friday, March 01, 2019—Research suggests that as many as 43% of patients with multiple sclerosis (MS) do not take a disease-modifying treatment (DMT) for the first 2 years of their diagnosis or long…

Comparative Protein Expression Analysis for Precision Diagnosis of Multiple Sclerosis

Friday, March 01, 2019—Gene coexpression with transcriptome analysis, a measure of what genes are actually expressed in an individual, has been used to distinguish patients with relapsing-remitting …

Alemtuzumab Effective for Treatment of MS Over 8 Years of Follow Up

Friday, March 01, 2019—After 8 years of treatment with alemtuzumab (Lemtrada; Sanofi, Bridgewater, NJ), patients treated with 3 or more courses of the drug had an annualized relapse rate (ARR) of 0.…

Positive Results from Phase 2 Clinical Trials of Evobrutinib for Multiple Sclerosis

Friday, March 01, 2019—After 24 weeks of treatment, patients treated with 75 mg of evobrutinib (EMD Serono, Rockland, MA) 2 or 4 times per day had significantly fewer T1 gadolinium-enhancing (Gd+) l…

New Drug Application Novel for Oral Fumarate Accepted by Food and Drug Administration

Monday, February 25, 2019—The Food and Drug Administration (FDA) has accepted an application for diroximel fumarate (BIIB098; Alkermes, Waltham, MA and Biogen, Cambridge, MA) for the treatment of relap…

Multiple Sclerosis Prevalence May Be Twice As High as Previously Thought

Tuesday, February 19, 2019—A study published in the journal Neurology suggests prevalence of multiple sclerosis (MS) in the US is 913,925 -- more than twice the previous estimate of 400,000 pe…


Contact Info

For advertising rates and opportunities:
Wendy Terry

About Practical Neurology

Launched in 2002, Practical Neurology is a publication uniquely dedicated to presenting current approaches to patient management, synthesis of emerging research and data, and analysis of industry news with a goal to facilitate practical application and improved clinical practice for all neurologists. Our straightforward articles give neurologists tools they can immediately put into practice.